Syros Pharmaceuticals Inc (SYRS)
0.2743
-0.09
(-23.78%)
USD |
NASDAQ |
Nov 14, 16:00
0.2793
0.00 (0.00%)
After-Hours: 16:37
Syros Pharmaceuticals Shareholders Equity (Quarterly): -11.12M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -11.12M |
| June 30, 2024 | -6.352M |
| March 31, 2024 | 15.06M |
| December 31, 2023 | 16.66M |
| September 30, 2023 | 36.30M |
| June 30, 2023 | 73.24M |
| March 31, 2023 | 106.75M |
| December 31, 2022 | 127.74M |
| September 30, 2022 | 129.17M |
| June 30, 2022 | 31.02M |
| March 31, 2022 | 62.74M |
| December 31, 2021 | 85.22M |
| September 30, 2021 | 106.06M |
| June 30, 2021 | 129.98M |
| March 31, 2021 | 149.88M |
| December 31, 2020 | 90.55M |
| September 30, 2020 | 45.94M |
| June 30, 2020 | 62.41M |
| Date | Value |
|---|---|
| March 31, 2020 | 76.54M |
| December 31, 2019 | 79.18M |
| September 30, 2019 | 94.57M |
| June 30, 2019 | 111.92M |
| March 31, 2019 | 64.02M |
| December 31, 2018 | 78.59M |
| September 30, 2018 | 94.84M |
| June 30, 2018 | 108.71M |
| March 31, 2018 | 104.50M |
| December 31, 2017 | 65.32M |
| September 30, 2017 | 78.59M |
| June 30, 2017 | 91.08M |
| March 31, 2017 | 70.14M |
| December 31, 2016 | 80.60M |
| September 30, 2016 | 90.78M |
| June 30, 2016 | 53.39M |
| March 31, 2016 | 63.92M |
| December 31, 2015 | 34.05M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-11.12M
Minimum
Sep 2024
149.88M
Maximum
Mar 2021
70.35M
Average
74.89M
Median
Shareholders Equity (Quarterly) Benchmarks
| Baxter International Inc | 7.643B |
| AbbVie Inc | 6.032B |
| Elanco Animal Health Inc | 6.523B |
| Opus Genetics Inc | 40.64M |
| Entrada Therapeutics Inc | 422.45M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 85.00M |
| Total Liabilities (Quarterly) | 96.12M |